A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV) (EMBRACE)

• ClinicalTrials.gov Identifier: NCT05996471
• Recruitment Status: Active, not recruiting
• First Posted: August 18, 2023
• Last Update Posted: April 3, 2024
• Sponsor: ViiV Healthcare
• Information provided by (Responsible Party): ViiV Healthcare

Study Description

Brief Summary:

The study aims at evaluating the efficacy of VH3810109, dosed in accordance with the dosing schedule as either intravenous (IV) infusion or subcutaneous (SC) infusion with recombinant hyaluronidase (rHuPH20), in combination with cabotegravir (CAB) intramuscular (IM) dosed in accordance with the dosing schedule in virologically suppressed, Antiretroviral therapy (ART)-experienced adult participants living with HIV.

Condition or disease	Intervention/treatment	Phase
HIV Infections	Biological: VH3810109; Drug: Cabotegravir; Drug: Standard of care (SOC); Biological: rHuPH20	Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 45 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase 2b Multicenter, Randomized, Open-Label Study Comparing the Efficacy, Safety, PK, and Tolerability of VH3810109, Administered Either Intravenously Or As A Subcutaneous Infusion With rHuPH20, in Combination With CAB LA to Standard of Care in Virologically Suppressed Adults Living With HIV
• Actual Study Start Date: August 17, 2023
• Estimated Primary Completion Date: November 29, 2024
• Estimated Study Completion Date: May 15, 2026

Arms and Interventions

Arm	Intervention/treatment
Experimental: Participants Receiving VH3810109 Plus Cabotegravir	Biological: VH3810109; VH3810109 will be administered.; Drug: Cabotegravir; Cabotegravir will be administered.
Experimental: Participants Receiving VH3810109 Plus rHuPH20 Plus Cabotegravir	Biological: VH3810109; VH3810109 will be administered.; Drug: Cabotegravir; Cabotegravir will be administered.; Biological: rHuPH20; rHuPH20 will be administered.
Active Comparator: Participants Receiving Standard of Care (SOC) Antiretroviral Therapy (ART)	Drug: Standard of care (SOC); Pre-baseline SOC antiretroviral therapy (ART) will be administered.

Outcome Measures

Primary Outcome Measures :

1. Number of Participants with Plasma HIV-1 Ribonucleic acid (RNA) Greater Than or Equal to (≥)50 Copies per Millilitre (c/mL) per Snapshot Algorithm at Month 6 [ Time Frame: Month 6 ]

Secondary Outcome Measures :

1. Number of Participants with Serious Adverse Events (SAEs), Deaths, and Adverse Events (AEs) Leading to Discontinuation of Investigational Product (IP) [ Time Frame: Up to Month 24 ]
2. Number of Participants with Grade 3-4 AEs [ Time Frame: Up to Month 24 ]
3. Number of Participants with Laboratory Abnormalities [ Time Frame: Up to Month 24 ]
4. Number of Participants with Grade 1-4 Injection Site Reactions [ Time Frame: Up to Month 24 ]
5. Number of Participants Meeting Confirmed Virologic Failure (CVF) Criteria Through Month 24 [ Time Frame: Up to Month 24 ]
6. Number of Participants with Plasma HIV-1 RNA ≥50 c/mL per Snapshot Algorithm Over Time [ Time Frame: Up to Month 24 ]
7. Number of Participants with Plasma HIV-1 RNA Less Than (<)50 c/mL per Snapshot Algorithm Over Time [ Time Frame: Up to Month 24 ]
8. Number of Participants with HIV Disease Progression [ Time Frame: Up to Month 24 ]
9. Serum Concentrations of VH3810109 [ Time Frame: Up to Month 24 ]
10. Plasma Concentrations of Cabotegravir [ Time Frame: Up to Month 24 ]
11. Absolute Value for Cluster of Differentiation 4 (CD4+) T-Cell Count [ Time Frame: Up to Month 24 ]
12. Change From Baseline in CD4+ T-Cell Count [ Time Frame: Baseline (Day 1) and up to Month 24 ]
13. Absolute Value for Cluster of Differentiation 8 (CD8+) T-Cell Count [ Time Frame: Up to Month 24 ]
14. Change From Baseline in CD8+ T-Cell Count [ Time Frame: Baseline (Day 1) up to Month 24 ]
15. Number of Participants with Anti-VH3810109 Antibodies [ Time Frame: Up to Month 24 ]
16. Number of Participants with Neutralizing Antibodies Against VH3810109 [ Time Frame: Up to Month 24 ]
17. Number of Participants with Treatment-emergent Genotypic Resistance [ Time Frame: Up to Month 24 ]
18. Number of Participants with Treatment-emergent Phenotypic Resistance [ Time Frame: Up to Month 24 ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 70 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion criteria

Age

1. Participant must be 18 to 70 years of age inclusive, at the time of signing the informed consent.

   Type of Participant and Disease Characteristics

2. Must be on uninterrupted current regimen for at least 6 months prior to Screening. Any prior switch, defined as a change of a single drug or multiple drugs simultaneously, must have occurred due to tolerability/safety, access to medications, or convenience/simplification, and must NOT have been done for treatment failure (HIV-1 RNA ≥200 c/mL).

   Acceptable stable - ARV regimens prior to Screening include at least one NRTI plus:

   • INI
   • NNRTI
   • Boosted PI (or atazanavir [ATV] unboosted)
   • Excludes current use of cabotegravir or fostemsavir

   The addition, removal, or switch of a drug(s) that has been used to treat HIV based on antiretroviral properties of the drug constitutes a change in ART with the following limited exceptions:

   • Historical changes in formulations of ART drugs or booster drugs will not constitute a change in ART regimen if the data support similar exposures and efficacy, and the change must have been at least 3 months prior to Screening.
   • Historical maternal perinatal use of an NRTI when given in addition to an ongoing HAART will not be considered a change in ART regimen.
   • A change in dosing scheme of the same drug from twice daily to once daily will not be considered a change in ART regimen if data support similar exposures and efficacy.
3. Documented evidence of at least two plasma HIV-1 RNA measurements <50 c/mL in the 12 months prior to Screening: one within the 6 to 12-month window, and one within 6 months prior to Screening;
4. Plasma HIV-1 RNA <50 c/mL at Screening;

5. Screening CD4+ T-cell count ≥350 cells/mm3:

   Weight

6. Body weight >=50 kg to <=115 kg.

   Sex

7. Male and/or female Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies, assuring minimal contraception requirements noted below.

All participants participating in the study should be counselled on safer sexual practices including the use and benefit/risk of effective barrier methods (e.g. male condom) and on the risk of HIV transmission to an uninfected partner.

1. Participants who are female at birth are eligible to participate if at least one of the following conditions applies:

   • Not pregnant or breastfeeding and at least one of the following conditions applies:

     • Is not a participant of childbearing potential (POCBP). OR
     • Is a POCBP and using an acceptable contraceptive method during the intervention period (at a minimum until after the last dose of study intervention). The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention.

   • A POCBP must have a negative highly sensitive (see Section 10.4) pregnancy test (urine or serum as required by local regulations) on Day 1, prior to the first dose of study intervention.

     * If a urine test cannot be confirmed as negative (e.g., an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.

   • The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a POCBP with an early undetected pregnancy.

   QTc 8. QTc Interval <450 msec.

   Phenotypic Sensitivity 9. Viral phenotypic sensitivity to VH3810109 based on IC90 of <=2 ug/mL and a Maximum Percent Inhibition >98% using the Monogram PhenoSense mAb Assay on sample obtained at a screening visit.

   Informed Consent 10. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

   Exclusion Criteria:

   Medical conditions:

   • Participants who are pregnant, breastfeeding, plan to become pregnant or breastfeed during the study

   • Participants having skin disease or disorder (i.e. infection, inflammation, dermatitis, eczema, drug rash, drug allergy, psoriasis, food allergy, urticaria) or tattoo overlying potential injection sites which may interfere with interpretation of injection site reactions or administration of VH3810109 or CAB
   • Participant has a gluteal implant/enhancement (including fillers) overlying the gluteus area or any other area which may significantly interfere with interpretation of injection site reactions
   • Participants with known history of cirrhosis with or without viral hepatitis co-infection
   • Participants with ongoing or clinically relevant pancreatitis
   • Untreated syphilis infection (positive rapid plasma reagin (RPR) at screening) without documentation of treatment. Participants who are at least 7 days post completed treatment are eligible if recruitment is open
   • Prior receipt of licensed or investigational HIV monoclonal antibody
   • Any evidence of an active Centers for Disease Control and Prevention (CDC) Stage 3 disease except cutaneous Kaposi's sarcoma not requiring systemic therapy. Historical or current CD4 cell counts less than 200 cells/mm^3 are not exclusionary
   • History of sensitivity to any of the study medications or their components or drugs of their class, or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation
   • Any condition which, in the opinion of the investigator, may interfere with the absorption, distribution, metabolism or excretion of the study drugs, cART or render the participant unable to take oral medication
   • Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening
   • Previous exposure to cabotegravir
   • Participant enrolled in a prior or concurrent clinical study that includes a drug intervention within the last 30 days
   • Participants with ongoing chronic hepatitis B virus infection
   • Participants with hepatitis C co-infection
   • Participants who in the investigator's judgment, pose a significant suicidality risk
   • Contraindications, as per the current Prescribing Information for cabotegravir.
   • Previous hypersensitivity reaction to cabotegravir or

   • Contraindicated co-administered drugs:

     • Anticonvulsants: Carbamazepine, oxcarbazepine, phenobarbital, phenytoin
     • Antimycobacterials: Rifabutin, rifampin, rifapentine
     • Glucocorticoid (systemic): Dexamethasone (more than a single-dose treatment)
     • Herbal product: St John's wort (Hypericum perforatum)

   Prior/Concomitant Therapy:

   • Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening.

   • Previous exposure to cabotegravir.

   • Treatment with any of the following agents within 60 days of screening:

     -radiation therapy;

     -cytotoxic chemotherapeutic agents;

     -any systemic immune suppressant.

   • Exposure to an experimental drug or experimental vaccine within either 28 days, 5 half lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is longer, prior to the first dose of study medication.
   • Current or anticipated need for chronic anti-coagulants.
   • Participants receiving any prohibited medication and who are unwilling or unable to switch to an alternate medication.

   Prior/Concurrent Clinical Study Experience • Participant enrolled in a prior or concurrent clinical study that includes a drug intervention within the last 30 days.

   Diagnostic Assessments

   • Any acute laboratory abnormality at Screening, which, in the opinion of the investigator, would preclude the participants inclusion in the study of an investigational compound.

   • Any evidence of viral resistance based on the presence of any major cabotegravir resistance-associated mutation [IAS-USA, 2022] in any historic resistance test result.

   • Any verified Grade 4 laboratory abnormality with the exception of Grade 4 triglycerides or lipid abnormalities. A single repeat test is allowed during the Screening period to verify a result.

   • Alanine aminotransferase (ALT) .3 times the upper limit of normal (ULN)

   • Creatinine clearance of <50 mL/min/1.73 m2 via using the refitted, race-neutral Chronic Kidney Disease Epidemiology Collaboration (CKD-EPIcr_R) method.
   • PT .Grade 2 (.1.25 ULN). A single repeat test is allowed during the Screening period to verify a result.

   Other Exclusion Criteria

   • To assess any potential impact on participant eligibility with regard to safety, the investigator must refer to the IB and supplements, approved product labels, and/or local prescribing information for detailed information regarding warnings, precautions, contraindications, AEs, drug interactions, and other significant data pertaining to the study drugs.

Contacts and Locations

Locations

United States, Alabama

GSK Investigational Site

Birmingham, Alabama, United States, 35294

United States, California

GSK Investigational Site

Bakersfield, California, United States, 93301

GSK Investigational Site

Los Angeles, California, United States, 90027

GSK Investigational Site

Los Angeles, California, United States, 90069

GSK Investigational Site

Palm Springs, California, United States, 92262

GSK Investigational Site

Sacramento, California, United States, 95825

GSK Investigational Site

San Francisco, California, United States, 94110

United States, Connecticut

GSK Investigational Site

New Haven, Connecticut, United States, 06510

United States, District of Columbia

GSK Investigational Site

Washington, District of Columbia, United States, 20007

GSK Investigational Site

Washington, District of Columbia, United States, 20037

United States, Florida

GSK Investigational Site

Fort Lauderdale, Florida, United States, 33308

GSK Investigational Site

Fort Pierce, Florida, United States, 34982

GSK Investigational Site

Miami, Florida, United States, 33133

GSK Investigational Site

Orlando, Florida, United States, 32803

GSK Investigational Site

Pensacola, Florida, United States, 32504

GSK Investigational Site

Sarasota, Florida, United States, 34237

GSK Investigational Site

Vero Beach, Florida, United States, 32960

GSK Investigational Site

West Palm Beach, Florida, United States, 33401

United States, Georgia

GSK Investigational Site

Decatur, Georgia, United States, 30033

United States, Illinois

GSK Investigational Site

Chicago, Illinois, United States, 60611

United States, Massachusetts

GSK Investigational Site

Boston, Massachusetts, United States, 02115

GSK Investigational Site

Springfield, Massachusetts, United States, 01105

United States, Michigan

GSK Investigational Site

Southfield, Michigan, United States, 48075

United States, Missouri

GSK Investigational Site

Columbia, Missouri, United States, 65212

United States, New Jersey

GSK Investigational Site

Newark, New Jersey, United States, 07102

United States, New Mexico

GSK Investigational Site

Albuquerque, New Mexico, United States, 87109

GSK Investigational Site

Santa Fe, New Mexico, United States, 87505

United States, New York

GSK Investigational Site

Bronx, New York, United States, 10461

GSK Investigational Site

Bronx, New York, United States, 10467

GSK Investigational Site

Manhasset, New York, United States, 11030

GSK Investigational Site

New York, New York, United States, 10029

GSK Investigational Site

New York, New York, United States, 10032

United States, North Carolina

GSK Investigational Site

Greensboro, North Carolina, United States, 27401-1209

United States, Ohio

GSK Investigational Site

Cincinnati, Ohio, United States, 45267

United States, Oregon

GSK Investigational Site

Portland, Oregon, United States, 97239

United States, Pennsylvania

GSK Investigational Site

Philadelphia, Pennsylvania, United States, 19104

United States, Tennessee

GSK Investigational Site

Nashville, Tennessee, United States, 37208

United States, Texas

GSK Investigational Site

Austin, Texas, United States, 78705

GSK Investigational Site

Dallas, Texas, United States, 75246

GSK Investigational Site

El Paso, Texas, United States, 79912

GSK Investigational Site

Houston, Texas, United States, 77030-1501

GSK Investigational Site

Houston, Texas, United States, 77098

United States, Wisconsin

GSK Investigational Site

Milwaukee, Wisconsin, United States, 53226

Puerto Rico

GSK Investigational Site

San Juan, Puerto Rico, 00909

GSK Investigational Site

San Juan, Puerto Rico, 909

Sponsors and Collaborators

ViiV Healthcare

More Information

• Responsible Party: ViiV Healthcare
• ClinicalTrials.gov Identifier: NCT05996471
• Other Study ID Numbers: 209639
• First Posted: August 18, 2023
• Last Update Posted: April 3, 2024
• Last Verified: March 2024

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Yes
• Plan Description: Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/
• Supporting Materials: Study Protocol; Statistical Analysis Plan (SAP); Informed Consent Form (ICF); Clinical Study Report (CSR)
• Time Frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
• Access Criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
• URL: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No

Keywords provided by ViiV Healthcare:

VH3810109; Cabotegravir; Standard of care; HIV; Long acting; Virologically Suppressed

Additional relevant MeSH terms:

HIV Infections; Blood-Borne Infections; Communicable Diseases; Infections; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; RNA Virus Infections; Virus Diseases; Genital Diseases; Urogenital Diseases; Immunologic Deficiency Syndromes; Immune System Diseases; Cabotegravir; HIV Integrase Inhibitors; Integrase Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action; Anti-HIV Agents; Anti-Retroviral Agents; Antiviral Agents; Anti-Infective Agents